PMGC Holdings Reports Strong Growth and New Partnerships
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 10 2026
0mins
Should l Buy ELAB?
Source: Benzinga
PMGC Holdings Inc. (ELAB) has seen its stock surge by 35.39% as it reaches a 20-day high, reflecting strong market interest following recent developments.
The company reported a 43% increase in total assets for fiscal year 2025, rising to approximately $12.87 million, alongside successful acquisitions in precision manufacturing. Additionally, PMGC's subsidiary, NorthStrive Biosciences, has amended its clinical trial agreement with MOA Life Plus for the EL-22 and EL-32 programs, which are focused on muscle preservation. This strategic move is expected to enhance the company's competitive position in the biopharmaceutical sector, driving future growth.
The implications of these developments are significant, as they not only improve PMGC's financial stability but also position the company favorably within the growing sectors of defense and biopharmaceuticals, ensuring long-term demand for its products.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ELAB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ELAB
About ELAB
PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. The Company manages and operates a diverse portfolio of five wholly owned subsidiaries: NorthStrive BioSciences Inc., PMGC Research Inc., PMGC Capital LLC, Pacific Sun Packaging Inc., and AGA Precision Systems LLC. NorthStrive BioSciences Inc. is a biopharmaceutical company focusing on the development and acquisition of aesthetic medicines and therapeutic products. PMGC Research Inc. is engaged in medical scientific research and development efforts. PMGC Capital LLC is a multi-strategy investment firm focused on direct investments, strategic lending, and acquiring undervalued companies and assets across diverse markets. Pacific Sun Packaging Inc. is a custom information technology packaging company. AGA Precision Systems LLC is a precision engineering and CNC machining company.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
PMGC Holdings Releases Annual Report for Fiscal Year 2025
- Capital Allocation Growth: PMGC Holdings achieved a 43% increase in total assets for fiscal year 2025, rising from approximately $8.99 million to $12.87 million, while shareholders' equity grew from about $6.66 million to $7.84 million, reflecting successful capital deployment and balance sheet expansion that enhances financial stability.
- Acquisition Strategy Implementation: During fiscal year 2025, PMGC completed three acquisitions in precision manufacturing and industrial packaging, with these businesses characterized by high technical barriers and mission-critical applications, which are expected to enhance the company's market competitiveness and customer retention.
- Industry Demand Drivers: The acquisitions position PMGC favorably within precision manufacturing and specialty IT hardware packaging sectors, with ongoing U.S. defense spending and data center infrastructure development expected to sustain demand for its products, ensuring long-term growth potential.
- Biopharmaceutical Advancements: PMGC's biopharmaceutical subsidiary, Northstrive Biosciences, advanced multiple clinical and preclinical initiatives in fiscal year 2025, focusing on muscle preservation, which is anticipated to open new market opportunities through potential combinations with GLP-1 therapies.
See More
ELAB Partners with Turbo-Jet for Long-Term Supply Agreement
- Long-Term Agreement: ELAB's AGA Precision Systems has signed a five-year long-term agreement with Turbo-Jet Products Co. to supply mission-critical components for commercial and defense programs, further solidifying AGA's role in the aerospace and defense supply chain.
- Significant Asset Growth: PMGC recently reported a 43% increase in total assets to $12.9 million in 2025, up from $9 million in 2024, indicating successful acquisition strategies in sectors with steady demand, enhancing its market competitiveness.
- Stock Price Surge: Following the partnership with Turbo-Jet, ELAB's stock rose by 7% on Tuesday, reflecting market optimism regarding the company's future growth potential, particularly in supporting defense projects.
- Successful ITAR Registration: PMGC's subsidiary SVM Machining has secured ITAR registration from the U.S. Department of State, allowing it to engage in controlled defense projects, thereby enhancing its capability to enter U.S. military supply chains and signaling future business expansion potential.
See More
AGA Precision Systems Signs Long-Term Agreement with Turbo-Jet Products
- Long-Term Agreement: AGA Precision Systems has executed a five-year Long-Term Agreement with Turbo-Jet Products to supply mission-critical aerospace and defense components, thereby ensuring a strategic partnership for future purchase orders.
- Compliance Enhancement: This agreement supports the execution of U.S. government and defense-related contracts, as AGA strengthens its position in the aerospace supply chain through AS9100 certification and ITAR compliance, ensuring high-quality and compliant component delivery.
- Market Positioning Improvement: By collaborating with Turbo-Jet, AGA not only solidifies its market position in the aerospace and defense sectors but also lays the groundwork for future business growth, particularly in meeting stringent Federal Acquisition Regulations.
- Technical Capability Showcase: AGA's precision CNC machining capabilities enable it to meet demanding technical specifications for complex metal processing, further enhancing its competitiveness in the aerospace, defense, and industrial sectors.
See More
PMGC Holdings Unit Amends Clinical Trial Agreement
- Clinical Trial Agreement Amendment: PMGC Holdings' subsidiary NorthStrive Biosciences amended its deal with MOA Life Plus to conduct human trials for EL-22 and EL-32, targeting muscle and lean mass preservation, which is expected to enhance the company's competitive edge in the biopharmaceutical sector.
- Stock Price Surge: PMGC Holdings' shares soared over 66% in Monday's pre-market trading, despite a 95% year-to-date decline, indicating a positive market reaction to the new clinical trials that may attract investor interest.
- Iterum Therapeutics Winding-Up Petition: Iterum Therapeutics filed a winding-up petition in Ireland, set for hearing on April 13, 2026; although its stock rose 110% in pre-market trading, it remains down 90% year-to-date, reflecting market concerns about its future prospects.
- FDA Approval for New Drug Application: Lantern Pharma's STAR-001 received FDA clearance for clinical trials targeting relapsed or refractory CNS cancers, with shares gaining over 17% in pre-market trading, despite a 63% year-to-date decline, indicating market anticipation for its new therapy.
See More
Leading Pre-Market Gainers Today — ELAB, ITRM, LTRN Among Stocks Rising Ahead of Market Open
PMGC Holdings Update: PMGC Holdings announced an amended deal with MOA Life Plus to conduct human trials for EL-22 and EL-32, focusing on muscle and lean mass preservation.
Iterum Therapeutics Developments: Iterum Therapeutics filed a winding-up petition in Ireland, set for a hearing on April 13, 2026, while also announcing a significant increase in its stock value.
Lantheus Pharma Progress: Lantheus Pharma received FDA clearance for its new drug application for STAR-001, aimed at treating relapsed or refractory CNS malignancies, and saw a notable rise in its stock.
Market Sentiment: U.S. equities showed positive movement amid ongoing tensions in the Middle East, with retail sentiment regarding the S&P 500 ETF categorized as "extremely bearish."
See More
PMGC Subsidiary Amends License Agreement with MOA
- License Agreement Amendment: PMGC Holdings Inc.'s wholly owned subsidiary, NorthStrive Biosciences, has amended its existing License Agreement with South Korea's MOA Life Plus Co., Ltd., updating the timelines and key development milestones for the EL-32 and EL-22 human clinical development programs, thereby enhancing the company's competitive position in the biopharmaceutical sector.
- Commitment to Development: This amendment not only reflects NorthStrive Biosciences' commitment to disciplined development planning but also indicates the company's ongoing efforts to advance its human health portfolio, which is expected to accelerate product launch timelines and improve market acceptance.
- Strategic Partnership Enhancement: By collaborating with MOA Life Plus, NorthStrive Biosciences can leverage MOA's expertise in biotechnology to further drive the development of innovative therapies, thereby increasing the company's influence in the global market.
- Market Outlook: As clinical development progresses for products like EL-22, NorthStrive Biosciences is poised to achieve breakthroughs in obesity treatment, particularly in preserving muscle mass, which will create new growth opportunities and enhance its standing in the biopharmaceutical industry.
See More
PMGC Holdings Releases Annual Report for Fiscal Year 2025
- Capital Allocation Growth: PMGC Holdings achieved a 43% increase in total assets for fiscal year 2025, rising from approximately $8.99 million to $12.87 million, while shareholders' equity grew from about $6.66 million to $7.84 million, reflecting successful capital deployment and balance sheet expansion that enhances financial stability.
- Acquisition Strategy Implementation: During fiscal year 2025, PMGC completed three acquisitions in precision manufacturing and industrial packaging, with these businesses characterized by high technical barriers and mission-critical applications, which are expected to enhance the company's market competitiveness and customer retention.
- Industry Demand Drivers: The acquisitions position PMGC favorably within precision manufacturing and specialty IT hardware packaging sectors, with ongoing U.S. defense spending and data center infrastructure development expected to sustain demand for its products, ensuring long-term growth potential.
- Biopharmaceutical Advancements: PMGC's biopharmaceutical subsidiary, Northstrive Biosciences, advanced multiple clinical and preclinical initiatives in fiscal year 2025, focusing on muscle preservation, which is anticipated to open new market opportunities through potential combinations with GLP-1 therapies.
See More
ELAB Partners with Turbo-Jet for Long-Term Supply Agreement
- Long-Term Agreement: ELAB's AGA Precision Systems has signed a five-year long-term agreement with Turbo-Jet Products Co. to supply mission-critical components for commercial and defense programs, further solidifying AGA's role in the aerospace and defense supply chain.
- Significant Asset Growth: PMGC recently reported a 43% increase in total assets to $12.9 million in 2025, up from $9 million in 2024, indicating successful acquisition strategies in sectors with steady demand, enhancing its market competitiveness.
- Stock Price Surge: Following the partnership with Turbo-Jet, ELAB's stock rose by 7% on Tuesday, reflecting market optimism regarding the company's future growth potential, particularly in supporting defense projects.
- Successful ITAR Registration: PMGC's subsidiary SVM Machining has secured ITAR registration from the U.S. Department of State, allowing it to engage in controlled defense projects, thereby enhancing its capability to enter U.S. military supply chains and signaling future business expansion potential.
See More
AGA Precision Systems Signs Long-Term Agreement with Turbo-Jet Products
- Long-Term Agreement: AGA Precision Systems has executed a five-year Long-Term Agreement with Turbo-Jet Products to supply mission-critical aerospace and defense components, thereby ensuring a strategic partnership for future purchase orders.
- Compliance Enhancement: This agreement supports the execution of U.S. government and defense-related contracts, as AGA strengthens its position in the aerospace supply chain through AS9100 certification and ITAR compliance, ensuring high-quality and compliant component delivery.
- Market Positioning Improvement: By collaborating with Turbo-Jet, AGA not only solidifies its market position in the aerospace and defense sectors but also lays the groundwork for future business growth, particularly in meeting stringent Federal Acquisition Regulations.
- Technical Capability Showcase: AGA's precision CNC machining capabilities enable it to meet demanding technical specifications for complex metal processing, further enhancing its competitiveness in the aerospace, defense, and industrial sectors.
See More
PMGC Holdings Unit Amends Clinical Trial Agreement
- Clinical Trial Agreement Amendment: PMGC Holdings' subsidiary NorthStrive Biosciences amended its deal with MOA Life Plus to conduct human trials for EL-22 and EL-32, targeting muscle and lean mass preservation, which is expected to enhance the company's competitive edge in the biopharmaceutical sector.
- Stock Price Surge: PMGC Holdings' shares soared over 66% in Monday's pre-market trading, despite a 95% year-to-date decline, indicating a positive market reaction to the new clinical trials that may attract investor interest.
- Iterum Therapeutics Winding-Up Petition: Iterum Therapeutics filed a winding-up petition in Ireland, set for hearing on April 13, 2026; although its stock rose 110% in pre-market trading, it remains down 90% year-to-date, reflecting market concerns about its future prospects.
- FDA Approval for New Drug Application: Lantern Pharma's STAR-001 received FDA clearance for clinical trials targeting relapsed or refractory CNS cancers, with shares gaining over 17% in pre-market trading, despite a 63% year-to-date decline, indicating market anticipation for its new therapy.
See More
Leading Pre-Market Gainers Today — ELAB, ITRM, LTRN Among Stocks Rising Ahead of Market Open
PMGC Holdings Update: PMGC Holdings announced an amended deal with MOA Life Plus to conduct human trials for EL-22 and EL-32, focusing on muscle and lean mass preservation.
Iterum Therapeutics Developments: Iterum Therapeutics filed a winding-up petition in Ireland, set for a hearing on April 13, 2026, while also announcing a significant increase in its stock value.
Lantheus Pharma Progress: Lantheus Pharma received FDA clearance for its new drug application for STAR-001, aimed at treating relapsed or refractory CNS malignancies, and saw a notable rise in its stock.
Market Sentiment: U.S. equities showed positive movement amid ongoing tensions in the Middle East, with retail sentiment regarding the S&P 500 ETF categorized as "extremely bearish."
See More
PMGC Subsidiary Amends License Agreement with MOA
- License Agreement Amendment: PMGC Holdings Inc.'s wholly owned subsidiary, NorthStrive Biosciences, has amended its existing License Agreement with South Korea's MOA Life Plus Co., Ltd., updating the timelines and key development milestones for the EL-32 and EL-22 human clinical development programs, thereby enhancing the company's competitive position in the biopharmaceutical sector.
- Commitment to Development: This amendment not only reflects NorthStrive Biosciences' commitment to disciplined development planning but also indicates the company's ongoing efforts to advance its human health portfolio, which is expected to accelerate product launch timelines and improve market acceptance.
- Strategic Partnership Enhancement: By collaborating with MOA Life Plus, NorthStrive Biosciences can leverage MOA's expertise in biotechnology to further drive the development of innovative therapies, thereby increasing the company's influence in the global market.
- Market Outlook: As clinical development progresses for products like EL-22, NorthStrive Biosciences is poised to achieve breakthroughs in obesity treatment, particularly in preserving muscle mass, which will create new growth opportunities and enhance its standing in the biopharmaceutical industry.
See More
